Identification of Bradycardia Following Remdesivir Administration Through the US Food and Drug Administration American College of Medical Toxicology COVID-19 Toxic Pharmacovigilance Project

IMPORTANCE: The rapid spread and mortality associated with COVID-19 emphasized a need for surveillance system development to identify adverse events (AEs) to emerging therapeutics. Bradycardia is a remdesivir infusion–associated AE listed in the US Food and Drug Administration–approved prescribing i...

Descripción completa

Detalles Bibliográficos
Autores principales: Devgun, Jason M., Zhang, Rongmei, Brent, Jeffrey, Wax, Paul, Burkhart, Keith, Meyn, Alison, Campleman, Sharan, Abston, Stephanie, Aldy, Kim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929701/
https://www.ncbi.nlm.nih.gov/pubmed/36787141
http://dx.doi.org/10.1001/jamanetworkopen.2022.55815

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929701/
https://www.ncbi.nlm.nih.gov/pubmed/36787141
http://dx.doi.org/10.1001/jamanetworkopen.2022.55815

Ejemplares similares